uu.seUppsala University Publications
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Inhibition of SYK or BTK augments venetoclax sensitivity in SHP1-negative/BCL-2-positive diffuse large B-cell lymphoma
Int Ctr Genet Engn & Biotechnol, Mol Hematol, Trieste, Italy.
Int Ctr Genet Engn & Biotechnol, Mol Hematol, Trieste, Italy.
Int Ctr Genet Engn & Biotechnol, Mol Hematol, Trieste, Italy.
Int Ctr Genet Engn & Biotechnol, Mol Hematol, Trieste, Italy.
Show others and affiliations
2019 (English)In: Leukemia, ISSN 0887-6924, E-ISSN 1476-5551, Vol. 33, no 10, p. 2416-2428Article in journal (Refereed) Published
Abstract [en]

The BCL-2 inhibitor venetoclax has only limited activity in DLBCL despite frequent BCL-2 overexpression. Since constitutive activation of the B cell receptor (BCR) pathway has been reported in both ABC and GCB DLBCL, we investigated whether targeting SYK or BTK will increase sensitivity of DLBCL cells to venetoclax. We report that pharmacological inhibition of SYK or BTK synergistically enhances venetoclax sensitivity in BCL-2-positive DLBCL cell lines with an activated BCR pathway in vitro and in a xenograft model in vivo, despite the only modest direct cytotoxic effect. We further show that these sensitizing effects are associated with inhibition of the downstream PI3K/AKT pathway and changes in the expression of MCL-1, BIM, and HRK. In addition, we show that BCR-dependent GCB DLBCL cells are characterized by deficiency of the phosphatase SHP1, a key negative regulator of the BCR pathway. Re-expression of SHP1 in GCB DBLCL cells reduces SYK, BLNK, and GSK3 phosphorylation and induces corresponding changes in MCL1, BIM, and HRK expression. Together, these findings suggest that SHP1 deficiency is responsible for the constitutive activation of the BCR pathway in GCB DLBCL and identify SHP1 and BCL-2 as potential predictive markers for response to treatment with a venetoclax/BCR inhibitor combination.

Place, publisher, year, edition, pages
NATURE PUBLISHING GROUP , 2019. Vol. 33, no 10, p. 2416-2428
National Category
Cancer and Oncology
Identifiers
URN: urn:nbn:se:uu:diva-395723DOI: 10.1038/s41375-019-0442-8ISI: 000488517000007PubMedID: 30872780OAI: oai:DiVA.org:uu-395723DiVA, id: diva2:1365313
Funder
EU, Horizon 2020, 692180-STREAMH2020-TWINN-2015Swedish Cancer SocietySwedish Research CouncilAvailable from: 2019-10-24 Created: 2019-10-24 Last updated: 2019-10-24Bibliographically approved

Open Access in DiVA

No full text in DiVA

Other links

Publisher's full textPubMed

Authority records BETA

Mansouri, Larry

Search in DiVA

By author/editor
Mansouri, Larry
By organisation
Science for Life Laboratory, SciLifeLabDepartment of Immunology, Genetics and Pathology
In the same journal
Leukemia
Cancer and Oncology

Search outside of DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 12 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf